2020 Chemotherapy Immunization 
pharmaphorum
DECEMBER 21, 2020
2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.
STAT
MARCH 6, 2023
Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LifeProNow
APRIL 6, 2023
Patients were treated with Imfinzi in combination with chemotherapy and bevacizumab followed by Imfinzi , Lynparza and bevacizumabas maintenance therapy. This number is expected to rise by almost 42% by 2040 to over 445,000 newly diagnosed patients and 314,000 deaths.
pharmaphorum
JANUARY 3, 2023
Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.
pharmaphorum
JULY 20, 2022
The study compared VB-111 plus paclitaxel chemotherapy to paclitaxel given on its own, but showed no significant difference between the two groups, with PFS and OS in both coming in at just over five months and 13 months, respectively.
European Pharmaceutical Review
MAY 4, 2023
Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2020; 19(10): 2044–56.
pharmaphorum
JANUARY 19, 2022
EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. In 2020, an estimated 2.2
Expert insights. Personalized for you.
126 
Let's personalize your content